Cogent Biosciences Stock Current Asset
| COGT Stock | USD 9.58 0.05 0.52% |
Cogent Biosciences fundamentals help investors to digest information that contributes to Cogent Biosciences' financial success or failures. It also enables traders to predict the movement of Cogent Stock. The fundamental analysis module provides a way to measure Cogent Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cogent Biosciences stock.
Non Current Assets Total is likely to gain to about 44.8 M in 2024, whereas Other Current Assets are likely to drop slightly above 3.4 M in 2024. Cogent | Current Asset |
Cogent Biosciences Company Current Asset Analysis
Cogent Biosciences' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Cogent Biosciences Current Asset | 37.62 M |
Most of Cogent Biosciences' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cogent Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cogent Current Asset Historical Pattern
Today, most investors in Cogent Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cogent Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cogent Biosciences current asset as a starting point in their analysis.
Cogent Biosciences Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Cogent Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Cogent Biosciences has a Current Asset of 37.62 M. This is 98.25% lower than that of the Biotechnology sector and 96.45% lower than that of the Health Care industry. The current asset for all United States stocks is 99.6% higher than that of the company.
Cogent Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cogent Biosciences' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cogent Biosciences could also be used in its relative valuation, which is a method of valuing Cogent Biosciences by comparing valuation metrics of similar companies.Cogent Biosciences is currently under evaluation in current asset category among its peers.
Cogent Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cogent Biosciences from analyzing Cogent Biosciences' financial statements. These drivers represent accounts that assess Cogent Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cogent Biosciences' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 21.9M | 124.4M | 332.3M | 679.0M | 611.1M | 641.7M | |
| Enterprise Value | (9.4M) | (112.5M) | 115.8M | 558.8M | 502.9M | 528.1M |
Cogent Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cogent Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cogent Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Cogent Fundamentals
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.44 | ||||
| Current Valuation | 851.13 M | ||||
| Shares Outstanding | 110.46 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 99.88 % | ||||
| Number Of Shares Shorted | 7.72 M | ||||
| Price To Earning | (5.03) X | ||||
| Price To Book | 5.19 X | ||||
| Price To Sales | 1,321 X | ||||
| Gross Profit | (121.63 M) | ||||
| EBITDA | (205.86 M) | ||||
| Net Income | (192.41 M) | ||||
| Cash And Equivalents | 325.56 M | ||||
| Cash Per Share | 4.95 X | ||||
| Total Debt | 18.85 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 11.96 X | ||||
| Book Value Per Share | 1.85 X | ||||
| Cash Flow From Operations | (153.62 M) | ||||
| Short Ratio | 6.09 X | ||||
| Earnings Per Share | (2.48) X | ||||
| Price To Earnings To Growth | (0.14) X | ||||
| Target Price | 16.36 | ||||
| Number Of Employees | 164 | ||||
| Beta | 0.021 | ||||
| Market Capitalization | 1.06 B | ||||
| Total Asset | 313.44 M | ||||
| Retained Earnings | (603.62 M) | ||||
| Working Capital | 232.6 M | ||||
| Current Asset | 37.62 M | ||||
| Current Liabilities | 21.06 M | ||||
| Net Asset | 313.44 M |
About Cogent Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cogent Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cogent Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cogent Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.